Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133802) titled 'Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Changchun BCHT Biotechnology Co.
Condition:
Prevention of Influenza
Intervention:
Biological: Placebo Group
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 2025
Target Sample Size: 66...